Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Cannabis-Related Disorders Medication

  • Author: Lawrence Genen, MD, MBA; Chief Editor: David Bienenfeld, MD  more...
 
Updated: Jun 23, 2014
 

Medication Summary

Short-term, low-dose benzodiazepines for treatment of significant anxiety associated with acute intoxication has been used. Clinicians are advised to use caution when administering benzodiazepines for the treatment of cannabis-induced anxiety, as the anxiety will invariable resolve with no medication over a short period. Drug therapies that diminish cravings for marijuana or intoxicating effects from marijuana use are currently not available.

Next

Anxiolytics

Class Summary

These agents depress all levels of CNS, which, in turn, reduces anxiety symptoms.

Lorazepam (Ativan)

 

Lorazepam is used for acute marijuana-associated panic or anxiety symptoms. Monitor vital signs carefully after administration. Watch for respiratory depression, ataxia, and somnolence/excess sedation. Amnesia may follow administration. Effects usually last 5-8 hours. Lorazepam is a sedative hypnotic with a short onset of effects and relatively long half-life. Increasing the action of GABA, which is a major inhibitory neurotransmitter in the brain, may depress all levels of the CNS, including limbic and reticular formation. When the patient must be sedated for more than 24 hours, this medication is excellent.

Previous
 
 
Contributor Information and Disclosures
Author

Lawrence Genen, MD, MBA Board Certified Psychiatrist; Diplomate, American Board of Psychiatry and Neurology; Founder, The Genen Group - A Multi-Specialty Psychiatry and Psychotherapy Practice

Disclosure: Nothing to disclose.

Coauthor(s)

William F Haning, III, MD, FASAM, DFAPA Professor of Psychiatry, Director of Graduate Affairs, Office of the Dean, Program Director, Addiction Psychiatry/Medicine, Department of Psychiatry, University of Hawaii, John A Burns School of Medicine; Principal Investigator and Co-Director, Pacific Addiction Research Center

William F Haning, III, MD, FASAM, DFAPA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Addiction Psychiatry, American Medical Association, American Psychiatric Association, American Society of Addiction Medicine, Association of Military Surgeons of the US, Hawaii Medical Association

Disclosure: Nothing to disclose.

John Franzen, MD Resident Physician, Department of Psychiatry, University of Nebraska-Creighton University

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

David Bienenfeld, MD Professor, Departments of Psychiatry and Geriatric Medicine, Wright State University, Boonshoft School of Medicine

David Bienenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, Association for Academic Psychiatry

Disclosure: Nothing to disclose.

Additional Contributors

Barry I Liskow, MD Professor of Psychiatry, Vice Chairman, Psychiatry Department, Director, Psychiatric Outpatient Clinic, The University of Kansas Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Robert C Daly, MB, ChB, MPH, BCh; Can M Savasman, MD; Caroline Fisher, MD, PhD; and Lina Cassandra Vawter, MD to the development and writing of this article.

References
  1. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part two of two. J Pain Palliat Care Pharmacother. 2009. 23(2):120-40. [Medline].

  2. Remnick D. Going the Distance. The New Yorker. Available at http://www.newyorker.com/reporting/2014/01/27/140127fa_fact_remnick?currentPage=all. Accessed: May 25, 2014.

  3. O'Brien M. Poll: Majority of Americans Support Efforts to Legalize Marijuana. NBC News. Available at http://www.nbcnews.com/storyline/legal-pot/poll-majority-americans-support-efforts-legalize-marijuana-n17416. Accessed: May 25, 2014.

  4. Frosch D. V.A. Easing Rules for Users of Medical Marijuana. The New York Times. Available at http://www.nytimes.com/2010/07/24/health/policy/24veterans.html?pagewanted=1&_r=1. Accessed: July 24, 2010.

  5. MacCoun R, Reuter P. Evaluating alternative cannabis regimes. Br J Psychiatry. 2001 Feb. 178:123-8. [Medline].

  6. Reinarman C, Cohen PD, Kaal HL. The limited relevance of drug policy: cannabis in Amsterdam and in San Francisco. Am J Public Health. 2004 May. 94(5):836-42. [Medline]. [Full Text].

  7. van den Brink W. Forum: Decriminalization of cannabis. Curr Opin Psychiatry. 2008 Mar. 21(2):122-6. [Medline].

  8. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007 Feb 13. 68(7):515-21. [Medline].

  9. Miller MC, et al. Medical marijuana and the mind. Harvard Mental Health Letter. April 2010. 26:1-4.

  10. Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA. 2012 Jan 11. 307(2):173-81. [Medline].

  11. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Apr 29. 82(17):1556-63. [Medline]. [Full Text].

  12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5. Washington D.C.: American Psychiatric Association; 2013.

  13. Burstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009 Mar. 11(1):109-19. [Medline]. [Full Text].

  14. Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant - do they exist?. Br J Pharmacol. 2010 Jun. 160(3):523-9. [Medline]. [Full Text].

  15. Ringen PA, Vaskinn A, Sundet K, et al. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol Med. 2009 Nov 6. 1-11. [Medline].

  16. Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, NSDUH Series H-30;. 2006. DHHS Publication No. SMA 06-4194:

  17. National Institute on Drug Abuse: Marijuana. National Institute on Drug Abuse. Available at http://www.drugabuse.gov/drugs-abuse/marijuana.

  18. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006 Oct. 36(10):1447-60. [Medline].

  19. Annual Report 2006: The State of the Drugs Problem in Europe. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).

  20. Wilson N, Cadet JL. Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review. J Addict Dis. 2009 Oct. 28(4):309-19. [Medline].

  21. Bosker WM, Kuypers KP, Theunissen EL, Surinx A, Blankespoor RJ, Skopp G, et al. Medicinal THC (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standardized Field Sobriety Tests. Addiction. 2012 May 4. [Medline].

  22. Barrigón ML, Gurpegui M, Ruiz-Veguilla M, et al. Temporal relationship of first-episode non-affective psychosis with cannabis use: a clinical verification of an epidemiological hypothesis. J Psychiatr Res. 2010 May. 44(7):413-20. [Medline].

  23. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010 Aug. 167(8):987-93. [Medline]. [Full Text].

  24. Kuepper R, van Os J, Lieb R, Wittchen HU, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011 Mar 1. 342:d738. [Medline]. [Full Text].

  25. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis Use and Earlier Onset of Psychosis: A Systematic Meta-analysis. Arch Gen Psychiatry. 2011 Jun. 68(6):555-61. [Medline].

  26. Peter Hecht. Report: African-Americans disproportionately targeted for pot. The Sacramento Bee. Available at http://blogs.sacbee.com/weed-wars/2010/06/report-african-americans-disproportionately-targeted-for-pot.html. Accessed: August 3, 2010.

  27. Lopez-Quintero C, Perez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011 May 1. 115(1-2):120-30. [Medline]. [Full Text].

  28. Preuss UW, Watzke AB, Zimmermann J, Wong JW, Schmidt CO. Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. Drug Alcohol Depend. 2010 Jan 15. 106(2-3):133-41. [Medline].

  29. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004 Nov. 161(11):1967-77. [Medline].

  30. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011 Dec 1. 119(1-2):123-9. [Medline].

  31. Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 2006 Apr. 28(2):155-63. [Medline].

  32. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict. 2009 Jan-Feb. 18(1):53-64. [Medline]. [Full Text].

  33. Degenhardt L, Dierker L, Chiu WT, et al. Evaluating the drug use "gateway" theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend. 2010 Apr 1. 108(1-2):84-97. [Medline]. [Full Text].

  34. Agrawal A, Lynskey MT. The genetic epidemiology of cannabis use, abuse and dependence. Addiction. 2006 Jun. 101(6):801-12. [Medline].

  35. Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis?. Can J Psychiatry. 2006 Aug. 51(9):556-65. [Medline].

  36. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009 Dec. 195(6):488-91. [Medline]. [Full Text].

  37. Gruber SA, Yurgelun-Todd DA. Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation. Brain Res Cogn Brain Res. 2005 Apr. 23(1):107-18. [Medline].

  38. Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl). 2005 Aug. 181(1):170-8. [Medline].

  39. Hurd YL, Wang X, Anderson V, Beck O, Minkoff H, Dow-Edwards D. Marijuana impairs growth in mid-gestation fetuses. Neurotoxicol Teratol. 2005 Mar-Apr. 27(2):221-9. [Medline].

  40. Iversen L. Cannabis and the brain. Brain. 2003 Jun. 126(Pt 6):1252-70. [Medline].

  41. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2005. Bethesday, MD: National Institute on Drug Abuse;. 2006. NIH Publication No. 06-5882:

  42. [Guideline] Kleber HD, Weiss RD, Anton RF, et al. Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry. 2006 Aug. 163(8 Suppl):5-82. [Medline].

  43. Ramaekers JG, Moeller MR, van Ruitenbeek P, et al. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. 2006 Nov 8. 85(2):114-22. [Medline].

  44. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006 Jul 20. 24(21):3394-400. [Medline].

  45. Whitcomb D. Marijuana legalization will be on California ballot. Reuters. Available at http://www.reuters.com/article/idUSTRE62O08U20100325. Accessed: July 24, 2010.

  46. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. 2006 Apr. 39(4):421-9. [Medline].

Previous
Next
 
Cannabis sativa.
The major psychoactive component of marijuana is tetrahydrocannabinol (THC).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.